Andrew Wingate

Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.

Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Cytrellis Biosystems, Inc. designs and develops aesthetic devices. The company was founded by William Gerald Austen and Doug A. Levinson and is headquartered in Boston, MA.

Percivia LLC engages in the research and development of vaccine and recombinant protein products. The company was founded in 2006 and is headquartered in Cambridge, MA.

Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million.